Filing Details

Accession Number:
0001209191-10-049835
Form Type:
4
Zero Holdings:
No
Publication Time:
2010-10-08 16:10:43
Reporting Period:
2010-10-07
Filing Date:
2010-10-08
Accepted Time:
2010-10-08 16:10:43
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1006281 Protalix Biotherapeutics Inc. PLX Biological Products, (No Disgnostic Substances) (2836) 650643773
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1385115 Yossi Maimon C/O Protalix Biotherapeutics, Inc.
2 Snunit Street, Science Park, Pob 455
Carmiel L3 20100
Vp, Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2010-10-07 70,000 $9.67 0 No 4 S Indirect By trust
Common Stock Acquisiton 2010-10-07 77,769 $0.97 0 No 4 M Indirect By trust
Common Stock Disposition 2010-10-07 7,769 $9.73 0 No 4 F Indirect By trust
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect By trust
No 4 M Indirect By trust
No 4 F Indirect By trust
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Options (Right to Buy) Disposition 2010-10-07 77,769 $0.00 77,769 $0.97
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
75,964 2016-09-19 No 4 M Direct
Footnotes
  1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
  2. The reporting person acquired 70,000 shares of common stock upon the exercise of 77,769 outstanding options on a cash-less exercise basis, all of which shares were sold by the reporting person. The Company retained 7,769 shares of common stock in connection with the cashless exercise.
  3. qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee upon the exercise of stock options must be registered in the name of a trustee.
  4. All options are fully vested.
  5. Does not include options to purchase 50,000 shares of common stock at an exercise price equal to $2.65 per share that expire on February 25, 2019, does not include 130,000 shares of common stock at an exercise price equal to $6.90 per share that expire on February 25, 2020 and does not include options to purchase 175,000 shares of common stock at an exercise price equal to $5.00 per share that expire on February 7, 2018.